DR-197 In-depth molecular characterization of liver metastases from BC patients
One out of 8 women will develop breast cancer (BC) in her lifetime and BC remains the main cause of cancer-related mortality for women in industrialized countries. Approximately 20–30% of patients with early stage BC will develop metastases. Liver metastases are present in ~50% of all metastatic BC patients. There is a clinical need to understand the heterogeneity in outcomes in patients with liver metastatic BC and to have biomarkers to guide the local and systemic treatment strategy for these patients. Here, we will perform an in-depth molecular characterization of liver metastases from BC patients. The ultimate goal is to refine existing and identify new potential treatment avenues for these patients with liver metastatic BC.
Christine Desmedt, Katholieke Universiteit Leuven, for the purposes of this Agreement represented by KU Leuven Research & Development, Belgium
Back to newsMore news
As chair of the DAB, Mariska Kool will take a helicopter view
Frank van Wijck, science journalist After the departure of Ele Visser, lawyer Mariska Kool from The Data Lawyers took over …
A Learning Healthcare System for Better Cancer Research and Care
Vast amounts of data are generated during cancer diagnosis and treatment every single day. Tissue samples are analyzed, data about …
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.